论文部分内容阅读
为探讨应用哈乐治疗前列腺增生症(BPH)的临床疗效、安全性、临床适应症及更有效的用药方法,分别应用日服哈乐0.2mg、0.4mg治疗前列腺增生症各30例,并用高特灵2mg作对照。结果表明,哈乐和高特灵对减轻BPH患者的临床症状、增加尿流率,减少残余尿及改善病人的生活质量安全有效。哈乐与高特灵的临床疗效无显著差异,而副作用发生率明显低于高特灵,尤其是心血管方面的不良反应。日服哈乐0.4mg较0.2mg改善症状更快速有效,并不明显增加其副作用,故对症状明显者可选用。认为哈乐是目前治疗BHP较理想的高选择性α_(1A)-AR阻滞剂。
In order to explore the clinical efficacy, safety, clinical indications and more effective methods of treatment of benign prostatic hyperplasia (BPH) with Harmony, 30 cases of benign prostatic hyperplasia Trane 2mg as a control. The results show that Harmony and Gauntling in relieving BPH patients clinical symptoms, increased urinary flow rate, reduce residual urine and improve the quality of life of patients is safe and effective. There was no significant difference in the clinical efficacy of Halor and Gortolol, but the incidence of side effects was significantly lower than that of Gatorade, especially cardiovascular adverse reactions. Haruna 0.4mg daily serving 0.2mg to improve symptoms faster and more effective, does not significantly increase their side effects, so the obvious symptoms can be used. Hara is considered to be the ideal treatment of BHP high selectivity α_ (1A) -AR blockers.